Get news on conferences, trials, symposium invites, and more. Sign up for updates
Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

Glowing glass vial of TheraSphere Glass Microspheres against blue background. TheraSphere Microsphere

TheraSphere™ Y-90 Glass Microspheres

About TheraSphere

Unique, optimal design for tumor control

  • The only Y-90 microsphere with radiation embedded throughout
  • Maximizes radiation per microsphere (RPM) while minimizing risk of stasis or reflux
  • Arrives in a personalized, sealed source vial with easy and safe set-up
  • Dose vial administration takes less than five minutes

See how TheraSphere is made

Precision-manufactured glass microspheres are the most powerful radiation therapy on the market.

Discover more TheraSphere product information
icon-person and heart.

Safety and efficacy

An FDA-approved Y-90 treatment for HCC, TheraSphere is an efficient and powerful HCC therapy with a good patient safety profile and proven, durable outcomes. TheraSphere’s unique ability to safely deliver high-dose radiation with fewer spheres allows for maximum absorbed dose and increased tumor response while preserving healthy tissue.¹ 

icon-target in liver.

Targeted for control

TheraSphere is uniquely engineered to have unmatched radiation per microsphere (RPM) to maximize repetitive and cumulative radiation exposure to tumor cells. This allows you to confidently destroy tumor cells with proven ablative dosing and helps drive complete pathological necrosis (CPN).​ And, the flexibility of personalized doses serves your treatment intent — whether curative or palliative.

Product details

TheraSphere Y-90 glass microspheres are precisely formulated with high-dose Y-90, delivered with targeted accuracy into hepatocellular carcinoma (HCC) tumors to improve tumor* response and provide longer overall patient survival. 2,3

  • Pure beta emitter
  • Average energy of 0.9367 MeV
  • Average tissue penetration range of 2.5 mm

Powerful interventional radiotherapy

  • Available personalized doses: 3 – 20 GBq (in 0.5 GBq increments), ranging from 750,000 to 5 million microspheres
  • Insoluble glass microspheres with a mean diameter of 20-30 µm 
  • Y-90 is an integral constituent of the glass 
icon-people.

Part of a holistic HCC treatment plan

Early treatment with TheraSphere allows multidisciplinary teams to maximize the probability of positive tumor response. In combination with other therapies, TheraSphere widens the field of treatment possibilities – to ultimately improve patient outcomes.

See Referring physician information

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

See reimbursement resources
envelope and letter icon.

Have your questions answered

Receive additional information to help determine if TheraSphere could be a treatment option for your patients.

Contact us

FAQs: TheraSphere Key Trial Outcomes

In both PREMIERE and TRACE prospective randomized controlled trials, Y-90 treatment showed longer time to tumor progression than cTACE and DEB-TACE respectively. SOURCE This means patients who received Y-90 went longer without their tumor growing or spreading when compared to treatments with TACE. DEFINITION SOURCE

Compared to locoregional therapies like ablation and cTACE, Y-90 radioembolization helped better control tumor growth and improve survival in certain patients with early or intermediate liver cancer.5, 9

In the PREMIERE trial, similar proportions of patients in each group had a response to therapy.3  While overall response rates may be comparable between therapies, Y-90 has been linked to more durable tumor control, which can lead to prolonged time to tumor progression (TTP). 3  SOURCE: time to progression, overall survival paragraph. 

Patients waiting for a liver transplant are more often treated with Y-90 because of its improved TTP. Y-90 may increase patient survival by improving the rate of transplant.3, 8 SOURCE: change in local practice paragraph

In the multicenter LEGACY study, 84% of patients with unresectable solitary HCC lesions achieved a complete response following treatment with TheraSphere.6

In the prospective RASER study, patients with very early or early-stage HCC treated with radiation segmentectomy using TheraSphere demonstrated a sustained complete response rate of 90%.7

TheraSphere Y-90 glass microspheres deliver beta emissions designed to maximize repetitive and cumulative radiation exposure, which leads to complete pathological necrosis (CPN) of liver tumor cells. 

Learn more about TheraSphere’s mechanism of action

References

  1. TARGET study: Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0.
  2. LEGACY study: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819. Percentage shown reflects patients who were eligible for tumor response assessment.
  3. DOSISPHERE-01: Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29.
  4. PREMIERE study: Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller F, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L and Lewandowski RJ. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma Gastroenterology. 2016 Dec;151(6):1155-1163.e2. doi: 10.1053/j.gastro.2016.08.029. Epub 2016 Aug 27. 
  5. TRACE study: Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, et al. 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE Phase II randomized controlled trial. Radiology. 2022;303(3). doi:10.1148/radiol.211806.
  6. LEGACY study: Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study. Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
  7. RASER study: Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study [published online ahead of print, 2022 May 23].  Lancet Gastroenterol Hepatol. 2022;S2468-1253(22)00091-7. doi:10.1016/S2468-1253(22)00091-7
  8. Y-90 Transplant study: Salem R, Kwong AJ, Kim N, Sze DY, Mehta N. Yttrium-90 Radioembolization Has Become the Most Utilized Bridging Treatment for Liver Transplant Candidates in the United States. J Vasc Interv Radiol. 2025;36(2):362-363. doi:10.1016/j.jvir.2024.10.034
  9. BCLC study: Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026;84(3):631-654. doi:10.1016/j.jhep.2025.10.020

*Refers to HCC or associated tumors 

TheraSphere indications, safety, and warnings

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.